President & COO Nnamdi Njoku reported a sale of 6,753 shares of Omnicell, Inc. (NASDAQ:OMCL) at ~$37.09 per share on August 15, 2026, and August 17, 2026, according to a SEC Form 4 filing.
Transaction summary Transaction value based on SEC Form 4 weighted average sale price ($37.09); post-transaction value based on August 17, 2026, market close ($36.03)
Key questions – To what extent was the sale discretionary? Approximately 54% of the disposal involved non-discretionary tax withholding to cover obligations arising from equity vesting, while the remaining 3,083 shares were sold under a Rule 10b5-1 trading plan. – When was the trading plan established? The sales were executed pursuant to a Rule 10b5-1 trading plan adopted by the President & COO on February 9, 2026, which allows for pre-scheduled transactions to avoid potential conflicts of interest. – What is the insider’s remaining interest in the company?
Nnamdi Njoku maintains a direct position of 161,223.5647 shares of common stock, representing a 0.35% ownership stake in the firm. – How has the stock performed leading up to this transaction? Shares of the healthcare technology company were priced at $36.03 as of the August 17, 2026 market close, contributing to a 14% return over the preceding 12-month period. Company Overview Company Snapshot – Omnicell provides healthcare technology solutions, including automated medication dispensing systems (Titan XT), point-of-care clinical workflow solutions, and central pharmacy automation services, generating revenue through software licensing, equipment sales, and managed services. – The company operates on a recurring revenue model, delivering integrated medication management and pharmacy automation platforms to hospitals and health systems, with revenue derived from equipment sales, software subscriptions, and ongoing managed services. – Omnicell serves hospital systems, health networks, and pharmacy operations across the United States and international markets,…